Table 1 Supplement

PANNS-EC Meta-analysis outcome

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Medication | Effect Size | 95%CI | Heterogeneity | df | *p* | I2 | Tau2 | Significance test Z | *p* |
| placebo | -3.89 | -6.86 – -2.93 | 8.91 | 4 | 0.063 | 55.1 | 0.662 | 7.93 | <0.001 |
| ziprasidone | -5.29 | -7.84 – -2.74 | 9.75 | 1 | 0.002 | 89.7% | 3.033 | 4.07 | <0.001 |
| levopromazine | -5.75 | -7.02 – -4.47  | 3.26 | 1 | 0.071 | 69.3% | 0.031 | 8.99 | <0.001 |
| haloperidol | -6.79 | -9.42 – -4.16  | 136.21 | 2 | <0.001 | 98.5% | 0.396 | 3.67 | <0.001 |
| risperidone + clonazepam | -7.5 | -9.13 – -5.87  | 0 | 0 | n.a. | n.a. | n.a. | 9 | <0.001 |
| lorazepam | -7.59 | -9.29 – -5.88 | 0.86 | 1 | 0.355 | 0% | <0.001 | 12.30 | <0.001 |
| risperidone + lorazepam | -7.8 | -7.95 – -7.65  | 0 | 0 | n.a. | n.a. | n.a. | 101.52 | <0.001 |
| haloperidol + lorazepam | -8.75 | -10.3 – -7.19  | 0 | 0 | n.a. | n.a. | n.a. | 7.09 | <0.001 |
| aripiprazole | -9.63 | -14.28 – -4.97  | 4.95 | 1 | 0.026 | 79.8% | 0.081 | 8.51 | <0.001 |
| olanzapine | -10.49 | -14.15 – -6.82  | 108.87 | 9 | <0.001 | 91.7% | 0.183 | 13.23 | <0.001 |
| risperidone | -14.8 | -17.43 – -12.17 | 0 | 0 | n.a. | n.a. | n.a. | 8.91 | <0.001 |
| haloperidol + promethazine | -15 | -17.52 – -12.48 | 0 | 0 | n.a. | n.a. | n.a. | 11.66 | <0.001 |

n.a. = not applicable

Total PANSS-EC change of all studies identifeid per antipschotic per exposure category. Effect sizes are in points of chanes on PANSS-EC 95%CI = 95% Confidence Interval. I2: the variation in ES attributable to heterogeneity, Z: Significance test(s) of ES=0

Table 2 Supplement

ACES Meta-analysis outcome

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Medication | Effect Size | 95%CI | Heterogeneity | df | *p* | I2 | Tau2 | Significance test Z | *p* |
| placebo | 0.7 | 0.52 – 0.88 | 5.71 | 3 | 0.126 | 47.5% | 0.016 | 7.58 | <0.001 |
| levopromazine | 1.35 | 1.05 – 1.64 | 3.26 | 1 | 0.071 | 69.3% | 0.031 | 8.99 | <0.001 |
| haloperidol | 1.4 | 0.65 – 2.14 | 136.21 | 2 | <0.001 | 98.5% | 0.396 | 3.67 | <0.001 |
| aripiprazole | 1.9 | 1.46 – 2.33 | 7.24 | 1 | 0.007 | 86.2% | 0.087 | 8.50 | <0.001 |
| olanzapine | 1.98 | 1.69 – 2.27 | 108.87 | 9 | <0.001 | 91.7% | 0.183 | 13.23 | <0.001 |
| lorazepam | 2.05 | 1.72 – 2.38 | 0.86 | 1 | 0.355 | 0% | <0.001 | 12.30 | <0.001 |
| haloperidol + lorazepam | 2.2 | 1.59 – 2.81 | 0 | 0 | n.a. | n.a. | n.a. | 7.09 | <0.001 |

n.a. = not applicable

Total ACES change of all studies identifeid per antipschotic per exposure category. Effect sizes are in points of chanes on ACES 95%CI = 95% Confidence Interval. I2: the variation in ES attributable to heterogeneity, Z: Significance test(s) of ES=0

Table 3 Supplement

CGI Meta-analysis outcome

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Medication | Effect Size | 95%CI | Heterogeneity | df | *p* | I2 | Tau2 | Significance test Z | *p* |
| ziprasidone | 1.54 | 0.79 – 1.61 -  | 4.93 | 1 | 0.26 | 79.7% | 0.195 | 4.41 | <0.001 |
| aripiprazole | 3.1 | 2.66 – 3.54 | 0 | 0 | n.a. | n.a. | n.a. | 13.91 | <0.001 |
| haloperidol | 3.2 | 2.87 – 3.51 | 0 | 0 | n.a. | n.a. | n.a. | 20 | <0.001 |
| olanzapine | 3.51 | 3.12 – 3.90 | 2.07 | 1 | 0.150 | 51.8% | 0.041 | 17.59 | <0.001 |

n.a. = not applicable

Total CGI change of all studies identifeid per antipschotic per exposure category. Effect sizes are in points of chanes on CGI 95%CI = 95% Confidence Interval. I2: the variation in ES attributable to heterogeneity, Z: Significance test(s) of ES=0